Wiley Bros.-aintree Capital »

Galectin Therapeutics shares owned by Wiley Bros.-aintree Capital

Quarter-by-quarter ownership of Galectin Therapeutics (GALT) shares owned by Wiley Bros.-aintree Capital from 13F filings

Historical chart of Wiley Bros.-aintree Capital investment in Galectin Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Galectin Therapeutics held by Wiley Bros.-aintree Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Galectin Therapeutics by Wiley Bros.-aintree Capital

Quarter filed Position value Share count Share price at filing
2026-03-31 $114k 41k 2.79

More positions owned by Wiley Bros.-aintree Capital

Apple (AAPL)
Ishares Tr Core S&p500 Etf (IVV)
Ishares Tr Core S&p Mcp Etf (IJH)
Microsoft Corporation (MSFT)
NVIDIA Corporation (NVDA)
Ishares Tr Core Us Aggbd Et (AGG)
Dimensional Etf Trust Intl Core Eqt Mk (DFAI)
Ishares Tr Core Msci Eafe (IEFA)
Broadcom (AVGO)
JPMorgan Chase & Co. (JPM)
Amazon (AMZN)
Alphabet Cap Stk Cl A (GOOGL)
State Str Spdr S&p 500 Etf T Tr Unit (SPY)
Vanguard Charlotte Fds Total Int Bd Etf (BNDX)
Johnson & Johnson (JNJ)

View all positions for Wiley Bros.-aintree Capital

Top funds holding Galectin Therapeutics

Vanguard Capital Management
Marshall Wace
Advisor Group Holdings
Susquehanna International
Dr. Jeffrey R. Jay, M.D.
BlackRock
Millennium Management
Sontag Advisory
Geode Capital Management
Two Sigma Investments
Commonwealth Equity Services
Citadel Advisors
Jane Street
Vanguard Fiduciary Trust
LPL Financial

View all funds holding Galectin Therapeutics